Several studies reported p300 can induce the expression of PD-L1 in liver cancer to impair CD8+ T cell-mediated anti-tumor immunity (Xiang et al., 2020; Guo et al., 2021), probably via acetylation of myocyte enhancer factor 2D (MEF2D). This evidence concerns the gene EP300 and neoplasm.